CTNNB1 and FYN |
catenin (cadherin-associated protein), beta 1, 88kDa |
FYN proto-oncogene, Src family tyrosine kinase |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Host Interactions of HIV factors
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Sema3A PAK dependent Axon repulsion
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- PECAM1 interactions
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- Cell surface interactions at the vascular wall
- GPVI-mediated activation cascade
|
|
- Dasatinib
- 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
|
|
|
CTNNB1 and LEF1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
lymphoid enhancer-binding factor 1 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
CTNNB1 and PYGO1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
pygopus family PHD finger 1 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- deactivation of the beta-catenin transactivating complex
|
|
|
|
|
CTNNB1 and TCF7L1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
transcription factor 7-like 1 (T-cell specific, HMG-box) |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- Degradation of beta-catenin by the destruction complex
- S37 mutants of beta-catenin aren't phosphorylated
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
CTNNB1 and EP300 |
catenin (cadherin-associated protein), beta 1, 88kDa |
E1A binding protein p300 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- NOTCH2 intracellular domain regulates transcription
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Mitotic G2-G2/M phases
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- G2/M Transition
- HATs acetylate histones
- RORA activates circadian gene expression
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Innate Immune System
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Cell Cycle, Mitotic
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Polo-like kinase mediated events
|
|
|
|
|
CTNNB1 and SMAD3 |
catenin (cadherin-associated protein), beta 1, 88kDa |
SMAD family member 3 |
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- truncations of AMER1 destabilize the destruction complex
- CDO in myogenesis
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Cytosolic sensors of pathogen-associated DNA
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- Myogenesis
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
DAB2 and SMAD2 |
Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) |
SMAD family member 2 |
- Formation of annular gap junctions
- Gap junction degradation
- Gap junction trafficking and regulation
- Gap junction trafficking
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
DAPK1 and MIB1 |
death-associated protein kinase 1 |
mindbomb E3 ubiquitin protein ligase 1 |
- Programmed Cell Death
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
- Phosphoaminophosphonic Acid-Adenylate Ester
- 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
|
|
|
|
DAPK1 and MAPK1 |
death-associated protein kinase 1 |
mitogen-activated protein kinase 1 |
- Programmed Cell Death
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
- 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
- Phosphoaminophosphonic Acid-Adenylate Ester
- 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
DAPK1 and MAPK3 |
death-associated protein kinase 1 |
mitogen-activated protein kinase 3 |
- Programmed Cell Death
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- Signaling by FGFR in disease
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Cellular Senescence
- ERKs are inactivated
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- Senescence-Associated Secretory Phenotype (SASP)
- ERK1 activation
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RNA Polymerase I Promoter Clearance
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- RNA Polymerase I Transcription
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- RNA Polymerase I Promoter Opening
- Nuclear Events (kinase and transcription factor activation)
|
- 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
- Phosphoaminophosphonic Acid-Adenylate Ester
- 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
|
- Sulindac
- Arsenic trioxide
- Purvalanol
- 5-iodotubercidin
|
|
|
DAPK1 and YWHAB |
death-associated protein kinase 1 |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta |
- Programmed Cell Death
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- Signaling by GPCR
- Signaling by FGFR in disease
- Activation of BH3-only proteins
- MEK activation
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Rap1 signalling
- Gastrin-CREB signalling pathway via PKC and MAPK
- SOS-mediated signalling
- SHC-mediated signalling
- Signaling by PDGF
- Regulation of mRNA stability by proteins that bind AU-rich elements
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Activation of BAD and translocation to mitochondria
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Frs2-mediated activation
- Adaptive Immune System
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- Translocation of GLUT4 to the plasma membrane
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- IRS-related events triggered by IGF1R
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- Programmed Cell Death
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Intrinsic Pathway for Apoptosis
- Butyrate Response Factor 1 (BRF1) destabilizes mRNA
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Tristetraprolin (TTP) destabilizes mRNA
- NGF signalling via TRKA from the plasma membrane
- SHC-related events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- ARMS-mediated activation
- Signaling by Hippo
- RAF activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- FRS2-mediated cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
- 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
- Phosphoaminophosphonic Acid-Adenylate Ester
- 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
|
|
|
|
DAXX and TGFBR2 |
death-domain associated protein |
transforming growth factor, beta receptor II (70/80kDa) |
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
DCC and SIAH2 |
DCC netrin 1 receptor |
siah E3 ubiquitin protein ligase 2 |
- DSCAM interactions
- Axon guidance
- Role of second messengers in netrin-1 signaling
- DCC mediated attractive signaling
- Programmed Cell Death
- Netrin mediated repulsion signals
- Netrin-1 signaling
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- Axon guidance
- Netrin-1 signaling
|
|
|
|
|
DCC and NTN1 |
DCC netrin 1 receptor |
netrin 1 |
- DSCAM interactions
- Axon guidance
- Role of second messengers in netrin-1 signaling
- DCC mediated attractive signaling
- Programmed Cell Death
- Netrin mediated repulsion signals
- Netrin-1 signaling
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- DSCAM interactions
- Axon guidance
- Role of second messengers in netrin-1 signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Netrin-1 signaling
|
|
|
|
|
DCC and MAPK3 |
DCC netrin 1 receptor |
mitogen-activated protein kinase 3 |
- DSCAM interactions
- Axon guidance
- Role of second messengers in netrin-1 signaling
- DCC mediated attractive signaling
- Programmed Cell Death
- Netrin mediated repulsion signals
- Netrin-1 signaling
- Role of DCC in regulating apoptosis
- Extrinsic Pathway
|
- Signaling by FGFR in disease
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Cellular Senescence
- ERKs are inactivated
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- Senescence-Associated Secretory Phenotype (SASP)
- ERK1 activation
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RNA Polymerase I Promoter Clearance
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- RNA Polymerase I Transcription
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- RNA Polymerase I Promoter Opening
- Nuclear Events (kinase and transcription factor activation)
|
|
- Sulindac
- Arsenic trioxide
- Purvalanol
- 5-iodotubercidin
|
|
|
DDX5 and PIK3CA |
DEAD (Asp-Glu-Ala-Asp) box helicase 5 |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- TCR signaling
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
|
|
|
|
DLX1 and SMAD4 |
distal-less homeobox 1 |
SMAD family member 4 |
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
DNMT3A and MYC |
DNA (cytosine-5-)-methyltransferase 3 alpha |
v-myc avian myelocytomatosis viral oncogene homolog |
- Chromatin modifying enzymes
- Chromatin organization
- Epigenetic regulation of gene expression
- PRC2 methylates histones and DNA
- RMTs methylate histone arginines
- DNA methylation
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
HBEGF and EGFR |
heparin-binding EGF-like growth factor |
epidermal growth factor receptor |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- EGFR Transactivation by Gastrin
- PI3K/AKT activation
- Uptake and actions of bacterial toxins
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Nuclear signaling by ERBB4
- SHC1 events in ERBB4 signaling
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Uptake and function of diphtheria toxin
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
DVL1 and CCDC88C |
dishevelled segment polarity protein 1 |
coiled-coil domain containing 88C |
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- WNT mediated activation of DVL
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- degradation of DVL
- negative regulation of TCF-dependent signaling by DVL-interacting proteins
- Signaling by Wnt
- Signaling by WNT in cancer
- PCP/CE pathway
- beta-catenin independent WNT signaling
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- negative regulation of TCF-dependent signaling by DVL-interacting proteins
- Signaling by WNT in cancer
|
|
|
|
|